Basking Biosciences

Cary, NC · Founded 2019 · CIK 0001824142 · Biotech · Private

Reversible von Willebrand Factor-targeting therapeutics for acute thrombotic conditions

baskingbiosciences.com →
Grants
$2.2M
2 awards
Sector median: 1
Raised
$29M
2 Form D · Nov 2023
35 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · A reversible aptamer based therapeutic to treat stroke$575,406
Private capital raisedForm D · SEC$1,901,122
Federal grantDepartment of Health and Human Services · Phase II · A reversible aptamer based therapeutic to treat stroke$1,656,236
Private capital raisedForm D · SEC$27,500,017
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2298Zya, Inc.—$37M
2299Cyclacel Pharmaceuticals, Inc.—$36M
2300Retrotope, Inc.—$32M
2301Basking Biosciences—$29M
2302GALATEA BIO INC—$3.7M
2303Relay Therapeutics—$30M
2304Acurx Pharmaceuticals, Inc.—$17M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 12 related persons
  • Aiden AcevesDirector
  • David AdairDirector
  • Hannah ChangDirector
  • Steve GillisDirector
  • Ryan HelonDirector
  • Dan MyersDirector
  • Thomas NeedhamDirector
  • Shahid NimjeeDirector
  • Ari NowacekDirector
  • Julia OwensDirector · Executive Officer · Promoter
  • Richard SheaDirector · Executive Officer · Promoter
  • Bruce SullengerDirector

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.